Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer

IF 3.3 4区医学 Q2 ONCOLOGY

Breast Cancer : Targets and Therapy Pub Date : 2024-01-01 DOI:10.2147/BCTT.S442707

Jian Jin, Jie Li, Yonghong Liu, Q. Shi, Bo Zhang, Yanting Ji, Pengfei Hu

{"title":"Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer","authors":"Jian Jin, Jie Li, Yonghong Liu, Q. Shi, Bo Zhang, Yanting Ji, Pengfei Hu","doi":"10.2147/BCTT.S442707","DOIUrl":null,"url":null,"abstract":"Background Breast cancer and thyroid cancer are two prevalent malignancies in women, and a potential association between the two diseases has been suggested. Methods This retrospective case-control study was conducted involving 97 patients with breast cancer and thyroid cancer (BC-TC group) and 97 age-matched patients with breast cancer alone (BC group). Thyroid hormone levels, including triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH), were analyzed in healthy controls, BC patients, and BC-TC patients. Results BC-TC patients exhibited a higher rate of estrogen receptor (ER) and progesterone receptor (PR) positivity compared to BC patients. Serum T3 levels were significantly decreased in BC and BC-TC patients compared to healthy controls. However, there was no significant difference in T3 levels between BC and BC-TC patients. Serum TSH levels were significantly higher in BC-TC patients compared to BC patients. Conclusion ER positivity, PR positivity, and serum TSH levels greater than 4.45 mU/L were independent risk factors for primary thyroid cancer in breast cancer patients.","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"79 20","pages":"15 - 22"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S442707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background Breast cancer and thyroid cancer are two prevalent malignancies in women, and a potential association between the two diseases has been suggested. Methods This retrospective case-control study was conducted involving 97 patients with breast cancer and thyroid cancer (BC-TC group) and 97 age-matched patients with breast cancer alone (BC group). Thyroid hormone levels, including triiodothyronine (T3), thyroxine (T4), free triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH), were analyzed in healthy controls, BC patients, and BC-TC patients. Results BC-TC patients exhibited a higher rate of estrogen receptor (ER) and progesterone receptor (PR) positivity compared to BC patients. Serum T3 levels were significantly decreased in BC and BC-TC patients compared to healthy controls. However, there was no significant difference in T3 levels between BC and BC-TC patients. Serum TSH levels were significantly higher in BC-TC patients compared to BC patients. Conclusion ER positivity, PR positivity, and serum TSH levels greater than 4.45 mU/L were independent risk factors for primary thyroid cancer in breast cancer patients.

查看原文本刊更多论文

甲状腺激素变化与乳腺癌合并原发性甲状腺癌有关

背景乳腺癌和甲状腺癌是女性中两种常见的恶性肿瘤，有人认为这两种疾病之间可能存在关联。方法该回顾性病例对照研究涉及 97 名乳腺癌合并甲状腺癌患者（BC-TC 组）和 97 名年龄匹配的单纯乳腺癌患者（BC 组）。研究人员分析了健康对照组、BC 患者和 BC-TC 患者的甲状腺激素水平，包括三碘甲状腺原氨酸（T3）、甲状腺素（T4）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）和促甲状腺激素（TSH）。结果 BC-TC 患者的雌激素受体（ER）和孕激素受体（PR）阳性率高于 BC 患者。与健康对照组相比，BC 和 BC-TC 患者的血清 T3 水平明显下降。但 BC 和 BC-TC 患者的 T3 水平无明显差异。与 BC 患者相比，BC-TC 患者的血清 TSH 水平明显升高。结论 ER阳性、PR阳性和血清TSH水平大于4.45 mU/L是乳腺癌患者罹患原发性甲状腺癌的独立危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊